Complaints Outcomes

Search

Search Results

Search Again
Pharmacist Registrant 30 (Feb 8, 2017)

The Inquiry Committee has reinstated pharmacist registrant’s registration which had previously been suspended for an indefinite period on December 23, 2016. Pursuant to Section 36 of the Health Professions Act, the Inquiry Committee has reached an Agreement with the pharmacist registrant whereby the registrant consented to undertakings involving regular monitoring for fitness to practice pharmacy. The undertakings include, but are not limited to:

  1. Complying with any and all treatment plans as recommended by his medical providers, including but not limited to the following:

    1. Regular and consistent attendance to his meetings with his mental health team; and
    2. Adherence to his medication regimen;

  2. That after returning to work in pharmacy setting, on every shift of employment at any pharmacy, the registrant will work alongside another pharmacist in good standing at all times;

     

  3. That prior to the commencement of new employment at any pharmacy, the registrant shall disclose to the pharmacy manager the limits and conditions of this Consent Agreement and ensure that arrangements are made in the pharmacy operations to accommodate the said limits and conditions:

    1. The registrant must ensure that the pharmacy manager and/or employer with whom the registrant secures employment submits a written statement to the College declaring:

      1. their awareness of the limits and conditions in; and
      2. their obligation to contact the College if they have questions or concerns about the registrant’s practice. This statement must be received within 48 hours of any change of employment and/or 48 hours of any change in pharmacy manager/employer.

    2. The registrant must inform a Complaints Officer in writing or via email of his places of employment as a pharmacist and report any changes of the location of his employment within 72 hours of such change.

December 23, 2016
(February 8, 2017 – Registration reinstated)

The Inquiry Committee, pursuant to section 36 of the Health Professions Act, has reached an agreement with the pharmacist registrant to suspend his registration as a pharmacist, effective December 23, 2016. The agreement remains in effect until further notice. The Inquiry Committee considers the agreement necessary to protect the public. The pharmacist registrant's name has been withheld, pursuant to s. 39.3(4) of the Health Professions Act.

Pharmacist Registrant 26 (Jan 3, 2017)

The Inquiry Committee has reinstated pharmacist registrant’s registration which had previously been suspended indefinitely on May 16, 2016. Pursuant to Section 36 of the Health Professions Act, the Inquiry Committee has reached an agreement with the pharmacist registrant whereby the registrant consented to undertakings involving regular monitoring for fitness to practice pharmacy. The undertakings include, but are not limited to:

  1. That the registrant will comply with all terms of registrant’s monitoring program with the company currently involved in registrant’s care and remain on this program for a minimum of three (3) years from the day registrant returns to active employment as a pharmacist;

  2. That registrant will continue counselling for one (1) year after registrant returns to work;

  3. That registrant will inform all managers and employers with whom registrant gains employment of registrant’s medical condition and the limits and conditions on registrant’s registration pursuant to this agreement;

  4. That registrant will ensure that all managers and employers with whom registrant gains employment submit a written statement to the College within 48 hours of securing employment, declaring their awareness of registrant’s medical condition and the agreement, how they will accommodate and supervise registrant working in the pharmacy, and that they will submit a weekly narcotic count for a minimum of three (3) months to the College or advise the College if any narcotic count concerns arise;

  5. That after returning to work in a pharmacy setting, registrant will provide work sign-in sheets on a monthly basis;

  6. That registrant will not work alone after returning to work in a pharmacy setting and that there must be overlapping shifts of at least one registrant during registrant’s work shift for a minimum of the first six (6) months that registrant returns to work;

  7. That after returning to work in a pharmacy setting, registrant will not be allowed to dispense narcotics;

  8. That after returning to work in a pharmacy setting, registrant will not handle or physically prepare prescriptions for narcotic, controlled, opioid and sedative drugs, including but not limited to Benzodiazepine, Dextroamphetamine and testosterone products and any Z-Group drugs;

  9. That after returning to work in a pharmacy setting, for the first six (6) months, registrant will not be allowed to dispense Controlled Substances ie. Benzodiazepine, Dextroamphetamine and testosterone products and any Z-Group drugs (which are not considered Controlled Substances);

  10. That after returning to work in a pharmacy setting, registrant will not be allowed to do narcotic or controlled substances or Z-Group drug counts;

  11. That after returning to work in a pharmacy setting, registrant will not dispose or deal with wastage or breakage of or otherwise handle any narcotic, controlled, opioid and sedative drugs, including but not limited to Benzodiazepine, Dextroamphetamine and testosterone products and any Z-Group drugs;

  12. That registrant will not have access to the narcotic-safe or physically process and/or otherwise prepare any prescriptions that require access to the narcotic safe;

  13. That registrant will not be involved in any way with ordering supplies of narcotic medications;

  14. That registrant will be restricted from acting in the following roles in registrant’s practice: 

    1. an owner or manager of a pharmacy;
    2. a director of a corporation that owns a pharmacy; and
    3. a preceptor;

     

  15. That registrant will be restricted from acting in the following roles in registrant’s practice: 

    1. all changes in places of employment as a pharmacist;
    2. all changes in residential address and phone number; and
    3. all changes in medical provider;

The agreement will remain in place for a minimum of five years from the date of execution of the agreement. The registrant will be assessed by the treating physician after six (6) months upon return to active employment to determine whether or not any of the above limits or conditions should be removed. The name of the registrant has been withheld in accordance with section 39.3(4)(a) of the Health Professions Act for the purposes of not identifying the personal health information of the registrant respecting the condition. The Inquiry Committee is satisfied that the undertakings will protect the public.


May 16, 2016
(January 3, 2017 – Registration Reinstated)

The Inquiry Committee, pursuant to section 36 of the Health Professions Act, has reached an agreement with the pharmacist registrant to voluntarily suspend the registration as a pharmacist effective May 16, 2016. The agreement remains in effect until further notice. The Inquiry Committee considers the agreement necessary to protect the public. The pharmacist registrant's name has been withheld pursuant to section 39.3(4) of the Health Professions Act.

Lum, King Cheong (Steven) (Jan 1, 2017)

Pursuant to s. 36(1) of the Health Professions Act, the Inquiry Committee has reached an agreement with King Cheong (Steven) Lum (the “Registrant”) to suspend his registration as a pharmacist for 365 consecutive days, from January 1, 2017 to December 31, 2017.

In or about April 2016, while pharmacy manager, director, and owner of a pharmacy, the Registrant discovered discrepancies between the on-hand quantities and computer quantities of 47 individual molecules of narcotic and controlled drugs and 21 individual molecules of benzodiazepines at the pharmacy. The most significant discrepancies were 165,998 tablets of Ratio-Oxycocet (oxycodone/acetaminophen 5mg/325mg), 1,030 tablets of Ratio-Lenoltec No. 3 (acetaminophen/caffeine/codeine 300mg/15mg/30mg), and 17,353 tablets of Mylan-Alprazolam 2mg. The Registrant had not noticed the discrepancies for many months until April 2016, and therefore the discrepancies had not been reported to Health Canada as required.

After an investigation, it was substantiated that while the Registrant was pharmacy manager, director, and owner of a pharmacy, he failed to maintain a standard of practice of the pharmacy profession and contravened the relevant provincial and federal legislation with respect to the following:

  • Management of inventory of narcotics, controlled drugs and targeted substances under his control to prevent loss or theft, including failure to count and reconcile all narcotics, controlled drugs and targeted substances at least every three months as required by Professional Practice Policy #65;
  • Failure to maintain records of purchases, sales and remaining inventory for narcotics and other controlled drugs;
  • Failure to make timely reports of losses of narcotics and other controlled drugs to Health Canada; and
  • Failure to adhere to s. 43 of the Narcotic Control Regulations, s. G.03.012 of the Food and Drug Regulations, and s. 7(1)(b) of the Benzodiazepines and Other Targeted Substances Regulations, in that he failed to take all reasonable steps that were necessary to protect narcotics, controlled drugs and targeted substances on the premises or under his control against loss or theft or to take steps necessary to ensure their security, including failure to count and reconcile narcotics, controlled drugs and targeted substances at least every three months.

The Inquiry Committee considered that the Registrant’s serious lack of judgment constituted professional misconduct.

Prior to reinstatement of his registration following the suspension period, the Registrant will be required to:

  • thoroughly review relevant legislative requirements and to sign a Declaration acknowledging his understanding of and compliance with the legislative requirements;
  • meet with the Inquiry Committee to discuss his reflections on his conduct and what he has learned;
  • successfully pass the College’s Jurisprudence Exam; and
  • pay a $30,000 fine.

The Registrant will also be limited from being a manager, director, or owner of a pharmacy, hold shares in any corporation that owns a pharmacy, and/or be a preceptor for a period of five years from the date that his suspension ends (commencing December 31, 2017).

The Inquiry Committee considers this Agreement necessary to protect the public, as well as send a clear message to the profession that the College does not tolerate this type of conduct.


May 20, 2016
(January 1, 2017 – Registration suspended)

The Inquiry Committee, pursuant to section 35(1) of the Health Professions Act, R.S.B.C. 1996, c. 183, for the purposes of public protection, has imposed limits and conditions on the practice of registrant King Cheong (Steven) Lum, effective May 20, 2016, pending completion of an investigation of his pharmacy practice. Until further notice, Mr. Lum has the following limits and conditions on his practice:

  1. He will be restricted from the following roles in his practice:

    1. Be an owner or manager of a pharmacy;
    2. Be a director of a corporation that owns a pharmacy; and
    3. Act as a preceptor;

     

  2. He will be restricted from doing the following in relation to narcotic and controlled drugs and substances:

    1. Placing orders; 
    2. Signing wholesaler/manufacturer invoices confirming receipt of orders, or have any sort of signing authority relating to such orders; and
    3. Conducting counts and/or reconciliation of inventory;

     

  3. Prior to the commencement of new employment at any pharmacy, he will inform every manager and employer of the pharmacy in which he gains employment of the limits and conditions on his license pursuant to this order, and will ensure that the pharmacy manager and employer submits a written statement to the College declaring their awareness of the limits and conditions and how the limits and conditions will be accommodated in the pharmacy.

The registrant was the pharmacy manager, director, and owner of a pharmacy, and did not fulfill the responsibilities of a pharmacy manager, director, and owner to operate a pharmacy that met legislative and practice standards. He had not established and/or enforced policies and procedures for inventory management and security and storage of narcotic and controlled drugs, enabling a grossly large quantity of narcotic and controlled medication to be lost and/or taken from the pharmacy and potentially diverted, causing potential harm to the public.

Elstak-Blackwell, Cassandra (Dec 14, 2016)

Cassandra Elstak-Blackwell has completed a term of suspension which ended on December 14, 2016, and her registration as a pharmacist has been reinstated as of December 15, 2016. 


November 15, 2016
(DECEMBER 14, 2016 - registration reinstated)

Pursuant to section 36 of the Health Professions Act, the Inquiry Committee has reached an agreement with Cassandra Elstak-Blackwell (the “Registrant”) to temporarily suspend her registration as a pharmacist for 30 days, effective November 15, 2016 to December 14, 2016.

On March 12, 2015, a pharmacist at the Registrant’s pharmacy dispensed allopurinol to a patient which interacted with her existing medication, azathioprine. The drug-drug interaction between allopurinol and azathioprine is serious and well-known. On April 3, 2015, the Registrant dispensed refill prescriptions for allopurinol and azathioprine to the patient. These refills were dispensed again the next month on May 29, 2015 by another pharmacist.  In May 2015, the patient began experiencing symptoms of pancytopenia and was admitted to the hospital.  The patient remained in the hospital for 18 days during which she received multiple blood transfusions and required blood tests to determine the cause of her symptoms.

The Inquiry Committee found that the Registrant did not conduct a PharmaNet review, failed to detect the drug-drug interaction and did not provide counseling when she dispensed the medications to the patient.  The Inquiry Committee determined that in the interest of public safety, a 30-day suspension of the Registrant’s licence and educational remediation was appropriate for addressing this incident.  The Registrant has completed her educational requirements to the Inquiry Committee’s satisfaction and is now entering a 30-day suspension period for her licence.  The Inquiry Committee considers this agreement necessary to protect the public.   

Pharmacist Registrant 28 (Dec 6, 2016)

The Inquiry Committee has reinstated pharmacist registrant’s registration which had previously been suspended indefinitely on June 14, 2016. Pursuant to Section 36 of the Health Professions Act, the Inquiry Committee has reached an agreement with the pharmacist registrant whereby the registrant consented to undertakings involving regular monitoring for fitness to practice pharmacy. The undertakings include, but are not limited to:

  1. Strictly adhering to registrant’s routine medical monitoring program with the institution currently involved in registrant’s care and remaining on the monitoring program for a minimum period of two (2) years following the registrant’s return to active employment as a pharmacist; 

  2. Continuing to attend the Twelve Step meetings and Health Professionals Recovery Group as stipulated in the registrant’s Recovery Management Agreement for a minimum of 2 years following the registrant’s return to active employment as a pharmacist;

  3. Informing all managers and employers with whom registrant gains employment of registrant’s medical condition and the limits and conditions on registrant’s registration pursuant to the agreement;

  4. Ensuring that all managers and employers with whom registrant gains employment submit a written statement to the College declaring their awareness of registrant’s medical condition and the agreement, and how they will accommodate and supervise registrant working in pharmacy;

  5. Not working in isolation after returning to work in a pharmacy setting and that at least 80% of the registrant’s working hours must be with another pharmacist;

  6. After returning to work in a pharmacy setting, registrant will not handle or physically prepare or dispense prescriptions for narcotic, controlled, opioid and sedative drugs, except if from time to time this is not possible, then registrant can only hand them to the patient and provide patient counselling;

  7. Not having access to narcotic-safe or physically process and/or otherwise prepare any prescriptions that require access to the narcotic safe;

  8. Not being involved in any way with ordering supplies of narcotic medications;

  9. Being restricted from acting in the following roles in registrant’s practice:

    1. an owner or manager of a pharmacy;
    2. a director of a corporation that owns a pharmacy; and
    3. a preceptor;

    4.  
  10. Notifying the College, in writing or via e-mail, of:

    1. all changes in registrant’s places of employment as a pharmacist;
    2. all changes in residential address and phone number; and
    3. all changes in medical provider.

The agreement will remain in place for a minimum of two years from the date of execution of the agreement, following which the registrant will be assessed by the treating physician to determine whether or not continuation of monitoring is necessary. The name of the registrant has been withheld in accordance with section 39.3(4)(a) of the Health Professions Act for the purposes of not identifying the personal health information of the registrant respecting the condition. The Inquiry Committee is satisfied that the undertakings will protect the public.


June 14, 2016
(December 6, 2016 - Registration Reinstated)

The Inquiry Committee, pursuant to Section 36 of the Health Professions Act, has reached an agreement with pharmacist registrant to suspend his registration as a pharmacist effective June 14, 2016. The agreement remains in effect until further notice. The Inquiry Committee considers the agreement necessary to protect the public. The registrant's name has been withheld, pursuant to 39.3(4) of the Health Professions Act.

Phalore, Jagbir (Nov 29, 2016)

Pursuant to s. 35(4) of the Health Professions Act, the Inquiry Committee has determined that the limits and conditions imposed on the practice of pharmacy by Mr. Jagbir Phalore on May 16, 2016 are no longer necessary.

Pursuant to s. 36(1) of the Health Professions Act, the Inquiry Committee has reached an agreement with Mr. Phalore, effective November 29, 2016, where he undertaken to always follow certain steps in his pharmacy practice, and to disclose these undertakings to employers and potential employers. He will also be restricted from acting the following roles in his practice:

  1. Be an owner or manager of a pharmacy;
  2. Be a director of a corporation that owns a pharmacy; and
  3. Act as a preceptor.

After two years from November 29, 2016, Mr. Phalore may request that the Inquiry Committee remove the above limits and conditions, subject to a further review of the case by the Inquiry Committee.

Pharmacist Registrant 27 (Nov 7, 2016)

The Inquiry Committee has reinstated pharmacist registrant’s registration which had previously been suspended for an indefinite period on June 10, 2016.   The pharmacist registrant’s name has been withheld pursuant to section 39.3(4) of the Health Professions Act

Li, Jin Tong (Oct 20, 2016)

Pursuant to s. 36(1) of the Health Professions Act, the Inquiry Committee has reached an agreement with Jin Tong (Tom) Li (the “Registrant”) to suspend his registration as a pharmacist for 540 consecutive days, from October 20, 2016 to April 13, 2018.

The Registrant acknowledged that between January 1, 2014 and December 22, 2014, he submitted fraudulent claims to PharmaCare over the PharmaNet system on over 2400 occasions. On all occasions, the Registrant had billed a high dollar value medication on PharmaNet, then reversed the medication to manipulate PharmaCare deductibles and to effectively allow patients to receive financial benefits from PharmaCare to which they were not entitled.

The Registrant also acknowledged that between January 1, 2013 and December 31, 2014, he had been the dispensing pharmacist and/or pharmacy manager responsible for multiple practice deficiencies including dispensing quantities in large excess of what had been authorized, dispensing from invalid prescriptions, dispensing from incomplete prescriptions, dispensing prescriptions under the incorrect prescriber’s name, dispensing incorrect medications, processing blood glucose test strips on PharmaNet in large excess of what could be accounted for by wholesaler invoices, and not keeping complete patient records and prescription documentation.

Prior to reinstatement of his registration following the suspension period, the Registrant will be required to:

  • thoroughly review relevant legislative requirements and to sign a Declaration acknowledging his understanding of and compliance with the legislative requirements;
  • to meet with the Inquiry Committee to discuss his reflections on his conduct and what he has learned; and
  • to complete an ethics course at his own expense.

The Registrant will also be limited from being a manager, director, or owner of a pharmacy, hold shares in any corporation that owns a pharmacy, and/or be a preceptor for a period of five years from the date that his suspension ends (commencing April 14, 2018).

The Inquiry Committee considers this agreement necessary to protect the public, as well as send a clear message to the profession that the College does not tolerate this type of conduct. 

McRae, Sarah (Oct 10, 2016)

Sarah McRae has completed a term of suspension which ended on October 9, 2016, and her registration as a pharmacist has been reinstated as of October 10, 2016.


September 10, 2016
(October 10, 2016 - Registration Reinstated)

Pursuant to section 36 of the Health Professions Act, the Inquiry Committee has reached an agreement with Sarah McRae (the “Registrant”) to temporarily suspend her registration as a pharmacist for 30 days, effective September 10, 2016 to October 9, 2016.

On March 12, 2015, a pharmacist at the Registrant’s pharmacy dispensed allopurinol to a patient which interacted with her existing medication, azathioprine. The drug-drug interaction between allopurinol and azathioprine is serious and well-known. On April 3, 2015, another pharmacist at the pharmacy dispensed refill prescriptions for allopurinol and azathioprine to the patient. These refills were dispensed again the next month on May 29, 2015 by the Registrant.  In May 2015, the patient began experiencing symptoms of pancytopenia and was admitted to the hospital.  The patient remained in the hospital for 18 days during which she received multiple blood transfusions and required blood tests to determine the cause of her symptoms.

The Inquiry Committee found that the Registrant did not conduct a PharmaNet review, failed to detect the drug-drug interaction and did not provide counselling when she dispensed the medications to the patient.  The Inquiry Committee determined that in the interest of public safety, a 1-month suspension of the Registrant’s licence and educational remediation was appropriate for addressing this incident.  The Registrant has completed her educational requirements to the Inquiry Committee’s satisfaction and is now entering a 30-day suspension period for her licence.  The Inquiry Committee considers this agreement necessary to protect the public.   

Pharmacist Registrant 24 (Aug 12, 2016)

Pharmacist Registrant 24 has satisfied terms of an agreement reached with the Inquiry Committee on April 22, 2016. Limits and conditions on pharmacist registrant’s registration as a pharmacist have now been removed. The pharmacist registrant’s name has been withheld pursuant to 39.3(4) of the Health Professions Act.

Pages